Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD
Using receptor‑enriched analysis of functional connectivity (REACT) on an open dataset (N=15), the study found that LSD alters FC maps associated not only with 5‑HT2A but also with 5‑HT1A, 5‑HT1B, D1 and D2 receptors, and that these changes correlate with distinct subjective components. Serotonergic receptor‑enriched FC related primarily to perceptual and selfhood alterations while dopaminergic receptor‑enriched FC related to cognitive effects, suggesting meaningful non‑5‑HT2A contributions to LSD's phenomenology.
Abstract
Rationale
LSD is the prototypical psychedelic. Despite a clear central role of the 5HT2a receptor in its mechanism of action, the contributions of additional receptors for which it shows affinity and agonist activity remain unclear.
Objectives
We employed receptor-enriched analysis of functional connectivity by targets (REACT) to explore differences in functional connectivity (FC) associated with the distributions of the primary targets of LSD—the 5HT1a, 5HT1b, 5HT2a, D1 and D2 receptors.
Methods
We performed secondary analyses of an openly available dataset (N = 15) to estimate the LSD-induced alterations in receptor-enriched FC maps associated with these systems. Principal component analysis (PCA) was employed as a dimension reduction strategy for subjective experiences associated with LSD captured by the Altered States of Consciousness (ASC) questionnaire. Correlations between these principal components as well as VAS ratings of subjective effects with receptor-enriched FC were explored.
Results
Compared to placebo, LSD produced differences in FC when the analysis was enriched with each of the primary serotonergic and dopaminergic receptors. Altered receptor-enriched FC showed relationships with the subjective effects of LSD on conscious experience, with serotonergic and dopaminergic systems being predominantly associated with perceptual effects and perceived selfhood as well as cognition respectively. These relationships were dissociable, with different receptors showing the same relationships within, but not between, the serotonergic and dopaminergic systems.
Conclusions
These exploratory findings provide new insights into the pharmacology of LSD and highlight the need for additional investigation of non-5HT2a-mediated mechanisms.
Research Summary of 'Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD'
Introduction
Psychedelic compounds profoundly alter conscious experience, and lysergic acid diethylamide (LSD) is the prototypical example that has been the subject of renewed neuroscientific interest. Previous neuroimaging work has documented system-level changes under LSD such as increased blood flow in primary visual cortex, reduced network integrity, and altered dynamics of integration and segregation. However, pharmacological functional MRI alone provides limited insight into molecular mechanisms, and although 5-HT2A receptor agonism has been shown to be necessary for many LSD effects, LSD also has affinity and agonist activity at multiple other serotonergic and dopaminergic receptors (including 5-HT1A/1B and D1/D2), making it difficult to delineate their distinct contributions in vivo. Lawn and colleagues set out to investigate how LSD modulates functional connectivity (FC) when analysis is informed by the spatial distributions of specific receptor systems. The study applied receptor-enriched analysis of functional connectivity by targets (REACT) to an existing within-subject resting-state fMRI dataset (LSD versus placebo) and examined whether receptor-enriched FC maps for 5-HT1A, 5-HT1B, 5-HT2A, D1 and D2 relate to subjective phenomenology measured with the Altered States of Consciousness (ASC) questionnaire and visual analogue scales (VAS). The goal was to explore dissociable serotonergic and dopaminergic contributions to perceptual, self-related and cognitive aspects of the LSD experience.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topic
- Author
- APA Citation
Lawn, T., Dipasquale, O., Vamvakas, A., Tsougos, I., Mehta, M. A., & Howard, M. A. (2022). Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD. Psychopharmacology, 239(6), 1797-1808. https://doi.org/10.1007/s00213-022-06117-5
References (20)
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
De Gregorio, D., Posa, L., Ochoa-Sanchez, R. et al. · Pharmacological Research (2016)
Hibicke, M., Gobbi, G. · Journal of Neuroscience (2020)
Dipasquale, O., Selvaggi, P., Veronese, M. et al. · NeuroImage (2019)
Jobst, B. M., Atasoy, S., Ponce-Alvarez, A. et al. · NeuroImage (2021)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Kraehenmann, R. ;., Pokorny, D. ;., Vollenweider, L. ;. et al. · Psychopharmacology (2017)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Luppi, A. I., Carhart-Harris, R. L., Roseman, L. et al. · NeuroImage (2021)
Show all 20 referencesShow fewer
Lenz, C., Dolder, P. C., Lang, U. E. et al. · Acta Psychiatrica Scandinavica (2017)
Nichols, D. E. · Pharmacological Reviews (2016)
Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)
Pokorny, T., Preller, K. H., Kraehenmann, R. et al. · European Neuropsychopharmacology (2016)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Preller, K. H., Razi, A., Zeidman, P. et al. · PNAS (2019)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Cited By (6)
Papers in Blossom that reference this study
Shinozuka, K., Jerotic, K., Mediano, P. A. M. et al. · Translational Psychiatry (2024)
Erritzoe, D., Timmermann, C., Godfrey, K. et al. · Nature Mental Health (2024)
Halman, A., Kong, G., Sarris, J. et al. · Journal of Psychopharmacology (2023)
Mallaroni, P., Mason, N. L., Reckweg, J. T. et al. · Clinical Pharmacology and Therapeutics (2023)
Prugger, J., Hirschfeld, T., Majic, T. et al. · Neuropsychopharmacology (2023)
Luppi, A. I., Hansen, J. Y., Adapa, R. et al. · Biorxiv (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.